Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Vascular Biosciences operates a company patent portfolio in the Biotechnology & Pharmaceuticals technology area. The data shows 2 pending office actions currently active. These actions are handled by distinct examiners, which indicates that the workload is divided between the personnel assigned to review them. This structure requires the applicant to maintain separate prosecution strategies for each active matter.
REYNOLDS, FRED H is the busiest examiner for this portfolio, with 1 pending office action under their review. Since the portfolio has 2 pending office actions total, this examiner is responsible for a portion of the current workload. The involvement of distinct art units suggests that the portfolio's subject matter is being evaluated under different technical focuses within the biotechnology sector.
A practitioner managing this portfolio must account for the perspectives of multiple examiners. Because each of the pending office actions is in one of the 2 distinct art units, the prosecution strategy may need to be customized to the specific requirements of those individual units. This level of distribution ensures that the progress of one application is independent of the other, allowing for varied outcomes.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (50%) |
| Double-patenting only | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| REYNOLDS, FRED H | 1 | 33.0% | +39.2% |
| POLIAKOVA-GEORGAN, EKATERINA | 1 | 64.0% | +18.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16998489 | Methods for Increasing the Selective Efficacy of Gene Therapy Using CAR Peptide and Heparan-Sulfate Mediated Macropinocytosis | REYNOLDS, FRED H | 85d overdue |
| 16908540 | Methods of Novel Therapeutic Candidate Identification Through Gene Expression Analysis in Vascular-Related Diseases | POLIAKOVA-GEORGAN, EKATERINA | 37d overdue |
| Art Unit | Apps |
|---|---|
| 1658 | 1 |
| 1637 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 16998489 | Methods for Increasing the Selective Efficacy of Gene Therapy Using CAR Peptide and Heparan-Sulfate Mediated Macropinocytosis | REYNOLDS, FRED H | 1658 | §112 | Final Rejection | 85d overdue | Pending | Aug 20, 2020 |
| 16908540 | Methods of Novel Therapeutic Candidate Identification Through Gene Expression Analysis in Vascular-Related Diseases | POLIAKOVA-GEORGAN, EKATERINA | 1637 | DP | Final Rejection | 37d overdue | Pending | Jun 22, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial